相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
Ming Lei et al.
CLINICAL CANCER RESEARCH (2021)
PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy
Soomin Ahn et al.
MODERN PATHOLOGY (2021)
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial
Huiyan Luo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
Ian Chau et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.
Lin Shen et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong-Mu Sun et al.
LANCET (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).
Jianming Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang et al.
LANCET ONCOLOGY (2020)
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer
Russell D. Petty et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis
Basile Njei et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Meta-analysis in clinical trials revisited
Rebecca DerSimonian et al.
CONTEMPORARY CLINICAL TRIALS (2015)
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
Suling J. Lin et al.
GUT (2015)
Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy
Christiane Maria Rosina Thallinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
分享论文
